Severe obesity in organ donors is not associated with adverse heart transplant outcomes.
In the COVID-19 era, there has been a decrease in heart transplant (HT) volumes.
Thoracic organ transplantation remains a viable treatment option in patients with Eisenmenger Syndrome, although these patients are considered higher risk than other potential transplant recipients.
Lower baseline eGFR and a history of coronary artery disease may predict the risk for hemodialysis after total artificial heart implantation.
Heart transplant patients admitted to the hospital with COVID-19 symptoms may be sicker than nontransplant patients, but they present with the same symptoms as the general population.
Most programs put live-donor transplants on hold.
COVID-19was found to be associated with a higher fatality rate in recipients of heart transplant.
Heart transplant (HT) recipients with COVID-19 infection have a case fatality rate of 25 percent.
Heart transplant with or without bridge to transplant LVAD therapy was found to be associated with greater 5-year survival compared with LVAD destination therapy in patients with end-stage heart failure.
Investigations into the presentation and prognosis of the novel coronavirus disease 2019 in patients who have received a heart transplant are needed.